EGFR and pancreatic neoplasm: In addition, because matuzumab is an IgG1 antibody to the EGFR able to mediate antibody-dependent cellular cytotoxicity, additional cytotoxic mechanisms may be involved in its effects in pancreatic cancer (Lo et al, 2003; Graeven et al, 2004).